- Home
- IGMS vs MLAB Comparison
IGMS vs MLAB Comparison
Compare IGMS & MLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- MLAB
- Stock Information
- Founded
- IGMS 1993
- MLAB 1982
- Country
- IGMS United States
- MLAB United States
- Employees
- IGMS N/A
- MLAB N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- MLAB Industrial Machinery/Components
- Sector
- IGMS Health Care
- MLAB Industrials
- Exchange
- IGMS Nasdaq
- MLAB Nasdaq
- Market Cap
- IGMS 524.1M
- MLAB 675.1M
- IPO Year
- IGMS 2019
- MLAB N/A
- Fundamental
- Price
- IGMS $9.31
- MLAB $117.96
- Analyst Decision
- IGMS Buy
- MLAB Hold
- Analyst Count
- IGMS 8
- MLAB 2
- Target Price
- IGMS $16.63
- MLAB $120.00
- AVG Volume (30 Days)
- IGMS 162.3K
- MLAB 29.2K
- Earning Date
- IGMS 08-14-2024
- MLAB 08-05-2024
- Dividend Yield
- IGMS N/A
- MLAB 0.54%
- EPS Growth
- IGMS N/A
- MLAB N/A
- EPS
- IGMS N/A
- MLAB N/A
- Revenue
- IGMS $2,911,000.00
- MLAB $223,712,000.00
- Revenue This Year
- IGMS $631.13
- MLAB $11.38
- Revenue Next Year
- IGMS N/A
- MLAB $5.77
- P/E Ratio
- IGMS N/A
- MLAB N/A
- Revenue Growth
- IGMS 74.00
- MLAB 2.02
- 52 Week Low
- IGMS $3.81
- MLAB $82.86
- 52 Week High
- IGMS $17.70
- MLAB $141.17
- Technical
- Relative Strength Index (RSI)
- IGMS 45.01
- MLAB 43.69
- Support Level
- IGMS $9.62
- MLAB $126.78
- Resistance Level
- IGMS $10.95
- MLAB $141.17
- Average True Range (ATR)
- IGMS 1.00
- MLAB 4.23
- MACD
- IGMS -0.05
- MLAB -2.61
- Stochastic Oscillator
- IGMS 18.06
- MLAB 4.56
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.